About
To deliver the first-in-class medicines to cancer patients
——
SynRx Therapeutics is an innovative R&D company focusing on the development of novel anti-tumor drugs using synthetic lethality approaches. We are currently exploring several first-in-class anti-tumor compounds, and preclinical studies are in progress.
Founder
Xiaochun Yu ,Professor,Founder and Chairman
Professor and Associate Dean, School of Life Sciences, Westlake University
Professor, University of Michigan Medical School
M.D., Beijing Medical University;
Ph.D, Kurume University, Japan
Published more than 100 academic papers.
